Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

417
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
417
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

340
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
340
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

368
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
368
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

171
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
171
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

203
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
203
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug Delivery Bias in No-Reflow.

JACC. Advances·2026
Same author

Congenital Penile Curvature Is Associated With Larger Penile Dimensions: A Matched Case-Control Study.

Andrology·2026
Same author

Lipoprotein(a), Coronary Complexity, and Stent-Related Outcomes: Meta-Analytic Insights for the Interventional Cardiologist.

Journal of clinical medicine·2026
Same author

Urodynamic de-obstruction and symptom improvement after thulium laser vaporization (ThuVAP): evidence from a prospective paired study.

The Canadian journal of urology·2026
Same author

Coronary arterial age for mortality prediction and risk reclassification in SCORE COVID-19 registry: When vascular age runs faster or slower than chronological age.

Age and ageing·2026
Same author

Evaluation and management of transient lower urinary tract symptoms (LUTS) after surgery for Benign prostatic obstruction (BPO): a systematic review.

Prostate cancer and prostatic diseases·2026
Same journal

Lipid-lowering therapies: the arrows in the quiver and future bullets.

Minerva cardiology and angiology·2026
Same journal

From population science to the utmost technical aspects: a glimpse at some of today's key cardiovascular research topics.

Minerva cardiology and angiology·2026
Same journal

Presepsin as a biomarker of coronary artery disease in type 2 diabetes along the immune-inflammatory continuum.

Minerva cardiology and angiology·2026
Same journal

Use of vericiguat in a patient with heart failure with reduced ejection fraction and transthyretin cardiac amyloidosis: a helpful therapeutic opportunity.

Minerva cardiology and angiology·2026
Same journal

Bridging cardiology and neurorehabilitation: toward integrated recovery after acute and chronic cardiac events.

Minerva cardiology and angiology·2026
Same journal

A new tool for risk stratification in transcatheter aortic valve intervention.

Minerva cardiology and angiology·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

648

Endovascular therapy for erectile dysfunction: current knowledge and future perspectives.

Giuseppe Sangiorgi1, Alessandra Pizzuto2, Nicolas Diehm3

  • 1Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy - gsangiorgi@gmail.com.

Minerva Cardiology and Angiology
|June 5, 2020
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED), often linked to penile artery atherosclerosis, impacts quality of life. New percutaneous treatments show promise for improving erectile function and patient well-being.

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.8K
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

1.2K

Related Experiment Videos

Last Updated: Dec 19, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

648
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.8K
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

1.2K

Area of Science:

  • Cardiovascular Medicine
  • Urology
  • Vascular Surgery

Background:

  • Erectile dysfunction (ED) significantly affects quality of life and relationships.
  • Atherosclerosis of penile arteries is a primary cause of ED, often indicating broader cardiovascular issues.
  • Iliac-pudendal-penile artery stenosis affects up to 75% of ED patients.

Purpose of the Study:

  • To review the normal anatomy and physiology of erection.
  • To explore the pathophysiology of erectile dysfunction.
  • To examine the link between ED and cardiovascular diseases.
  • To discuss emerging percutaneous treatment modalities for ED.

Main Methods:

  • Literature review focusing on erectile function, pathophysiology, cardiovascular links, and treatment.
  • Analysis of studies on percutaneous interventions for penile artery stenosis.

Main Results:

  • Atherosclerosis is a key cause of ED, necessitating cardiovascular assessment.
  • Percutaneous treatments for penile artery stenosis demonstrate positive angiographic outcomes.
  • These interventions significantly improve ED symptoms and quality of life.

Conclusions:

  • ED is strongly associated with penile artery atherosclerosis and systemic cardiovascular disease.
  • Percutaneous revascularization offers a promising therapeutic option for ED.
  • Restoring penile blood flow through endovascular approaches enhances erectile function and patient well-being.